Stem cell therapy in inflammatory bowel disease: Which, when and how?

Current Opinion in Gastroenterology

Volumn 29, Issue 4, 2013, Pages 384-390

  Van Deen, Welmoed K ^a,b   Oikonomopoulos, Angelos ^a   Hommes, Daniel W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

hematopoietic stem cells; inflammatory bowel disease; mesenchymal stem cells

Indexed keywords

CYCLOPHOSPHAMIDE; FIBRIN GLUE; GAMMA INTERFERON; GROWTH HORMONE; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 7; KERATINOCYTE GROWTH FACTOR; THYMOCYTE ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ADAPTIVE IMMUNITY; ADOPTIVE TRANSFER; ALLOTRANSPLANTATION; ANUS FISTULA; CAUSE OF DEATH; CELL MIGRATION; COLON MUCOSA; CROHN DISEASE; CROHN DISEASE ACTIVITY INDEX; DENDRITIC CELL; ENVIRONMENTAL FACTOR; EX VIVO STUDY; FEVER; FOLLOW UP; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GRAFT VERSUS HOST REACTION; HEALTH CARE QUALITY; HEMATOPOIETIC STEM CELL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOLOGY; HUMAN; IMMUNE RESPONSE; INFECTIOUS COMPLICATION; LYMPHOCYTOPENIA; MACROPHAGE; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; MULTICENTER STUDY (TOPIC); MULTIPLE SCLEROSIS; NATURAL KILLER CELL; NEUTROPHIL; NONHUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; OXIDATIVE STRESS; PATIENT SAFETY; PERSONAL EXPERIENCE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PLURIPOTENT STEM CELL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; REVIEW; STEM CELL MOBILIZATION; STEM CELL TRANSPLANTATION; SYSTEMIC LUPUS ERYTHEMATOSUS; TH1 CELL; TH17 CELL; TISSUE INJURY; TISSUE REGENERATION; ULCERATIVE COLITIS; UNITED KINGDOM; WEIGHT REDUCTION;

HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INFLAMMATORY BOWEL DISEASES; MESENCHYMAL STEM CELL TRANSPLANTATION; STEM CELL TRANSPLANTATION;

EID: 84879920950     PISSN: 02671379     EISSN: 15317056     Source Type: Journal    
DOI: 10.1097/MOG.0b013e328361f763     Document Type: Review

References (50)

1. Copelan EA. Hematopoietic stem-cell transplantation. N Engl J Med 2006; 354:1813-1826.
2. Snowden JA, Saccardi R, Allez M, et al. Haematopoietic SCT in severe autoimmune diseases: updated guidelines of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2012; 47:770-790.
3. Le Blanc K, Mougiakakos D. Multipotent mesenchymal stromal cells and the innate immune system. Nat Rev Immunol 2012; 12:383-396.
4. Baumgart DC, Sandborn WJ. Crohn's disease. Lancet 2012; 380:1590-1605.
5. Ordas I, Eckmann L, Talamini M, et al. Ulcerative colitis. Lancet 2012; 380:1606-1619.
6. Scharl M, Rogler G. Inflammatory bowel disease pathogenesis: what is new? Curr Opin Gastroenterol 2012; 28:301-309.
7. Christophi GP, Rong R, Holtzapple PG, et al. Immune markers and differential signaling networks in ulcerative colitis and Crohn's disease. Inflamm Bowel Dis 2012; 18:2342-2356.
8. Strober W, Fuss IJ. Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. Gastroenterology 2011; 140:1756-1767.
9. Jostins L, Ripke S, Weersma RK, et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 2012; 491:119-124.
10. Cario E. Commensal-innate immune miscommunication in IBD pathogenesis. Dig Dis 2012; 30:334-340.
11. Muraro PA, Douek DC, Packer A, et al. Thymic output generates a new and diverse TCR repertoire after autologous stem cell transplantation in multiple sclerosis patients. J Exp Med 2005; 201:805-816.
12. Alexander T, Thiel A, Rosen O, et al. Depletion of autoreactive immunologic memory followed by autologous hematopoietic stem cell transplantation in patients with refractory SLE induces long-term remission through de novo generation ofajuvenile and tolerant immune system. Blood 2009; 113:214-223.
13. Burt RK, Craig RM, Milanetti F, et al. Autologous nonmyeloablative hematopoietic stem cell transplantation in patients with severe anti-TNF refractory Crohn disease: long-term follow-up. Blood 2010; 116:6123-6132.
14. Cassinotti A, Onida F, Annaloro C, et al. P362. Autologous haematopoietic stem cell transplantation without CD34+ cell selection for refractory Crohn's disease: the Milan experience after 5 years. J Crohns Colitis 2012; 6:S153-S154.
15. Hommes DW, Duijvestein M, Zelinkova Z, et al. Long-term follow-up of autologous hematopoietic stem cell transplantation for severe refractory Crohn's disease. J Crohns Colitis 2011; 5:543-549.
16. Hawkey C, Allez M, Ardizzone S, et al. 9 Clinical and endocopic improvement following hemopoietic stem cell transplantation in the ASTIC trial. J Crohn's Colitis 2013; 7:S4.
17. Snowden JA, Pearce RM, Lee J, et al. Haematopoietic stem cell transplanta-tion (HSCT) in severe autoimmune diseases: analysis of UK outcomes from the British Society of Blood and Marrow Transplantation (BSBMT) data registry 1997-2009. Br J Haematol 2012; 157:742-746.
18. Farge D, Labopin M, Tyndall A, et al. Autologous hematopoietic stem cell transplantation for autoimmune diseases: an observational study on 12 years' experience from the European Group for Blood and Marrow Transplantation Working Party on Autoimmune Diseases. Haematologica 2010; 95:284-292.
19. Ditschkowski M, Einsele H, Schwerdtfeger R, et al. Improvement of inflam-matory bowel disease after allogeneic stem-cell transplantation. Transplanta-tion 2003; 75:1745-1747.
20. Marti JL, Mayordomo JI, Isla MD, et al. PBSC autotransplant for inflammatory bowel disease (IBD): a case of ulcerative colitis. Bone Marrow Transplant 2001; 28:109-110.
21. Yu LZ, Qian S, Hong M, et al. A case of ulcerative colitis associated with autoimmune hemolytic anemia successfully treated by autologous hemato-poietic stem cell transplantation. Am J Gastroenterol 2010; 105:2302-2304.
22. Oevermann L, Lang P, Feuchtinger T, et al. Immune reconstitution and strategies for rebuilding the immune system after haploidentical stem cell transplantation. Ann N Y Acad Sci 2012; 1266:161-170.
23. Toubert A, Glauzy S, Douay C, Clave E. Thymus and immune reconstitution after allogeneic hematopoietic stem cell transplantation in humans: never say never again. Tissue Antigens 2012; 79:83-89.
24. Delaney C, Heimfeld S, Brashem-Stein C, et al. Notch-mediated expansion of human cord blood progenitor cells capable of rapid myeloid reconstitution. Nat Med 2010; 16:232-236.
25. Eyrich M, Schreiber SC, Wollny G, et al. Predifferentiated human committed T-lymphoid progenitors promote peripheral T-cell re-constitution after stem cell transplantation in immunodeficient mice. Eur J Immunol 2011; 41:3596-3603.
26. de Lima M, McNiece I, Robinson SN, et al. Cord-blood engraftment with ex vivo mesenchymal-cell coculture. N Engl J Med 2012; 367:2305-2315.
27. Sivasubramaniyan K, Lehnen D, Ghazanfari R, et al. Phenotypic and functional heterogeneityof human bonemarrow-and amnion-derived MSCsubsets.Ann N Y Acad Sci 2012; 266:94-106.
28. Bassi G, Pacelli L, Carusone R, et al. Adipose-derived stromal cells (ASCs). Transfus Apher Sci 2012; 47:193-198.
29. English K. Mechanisms of mesenchymal stromal cell immunomodulation. Immunol Cell Biol 2013; 91:19-26.
30. Dazzi F, Lopes L, Weng L. Mesenchymal stromal cells: a key player in 'innate tolerance'? Immunology 2012; 137:206-213.
31. He XW, He XS, Lian L, et al. Systemic infusion of bone marrow-derived mesenchymal stem cells for treatment of experimental colitis in mice. Dig Dis Sci 2012; 57:3136-3144.
32. Castelo-Branco MT, Soares ID, Lopes DV, et al. Intraperitoneal but not intravenous cryopreserved mesenchymal stromal cells home to the inflamed colon and ameliorate experimental colitis. PLoS One 2012; 7:e33360.
33. Duijvestein M, Wildenberg ME, Welling MM, et al. Pretreatment with inter-feron-gamma enhances the therapeutic activity of mesenchymal stromal cells in animal models of colitis. Stem Cells 2011; 29:1549-1558.
34. Le Blanc K, Frassoni F, Ball L, et al. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet 2008; 371:1579-1586.
35. Bernardo ME, Ball LM, Cometa AM, et al. Co-infusion of ex vivo-expanded, parental MSCs prevents life-threatening acute GVHD, but does not reduce the risk of graft failure in pediatric patients undergoing allogeneic umbilical cord blood transplantation. Bone Marrow Transplant 2011; 46:200-207.
36. Martin PJ, Uberti JP, Soiffer RJ, et al. Prochymal improves response rates in patients with steroid-refractory acute graft versus host disease (SR-GVHD) involving the liver and gut: results of a randomized, placebo-controlled, multicenter phase III trial in GVHD. Biol Blood Marrow Transplant 2010; 16:S169-S170.
37. Garcia-Olmo D, Garcia-Arranz M, Herreros D, et al. A phase I clinical trial of the treatment of Crohn's fistula by adipose mesenchymal stem cell trans-plantation. Dis Colon Rectum 2005; 48:1416-1423.
38. Garcia-Olmo D, Herreros D, Pascual I, et al. Expanded adipose-derived stem cells for the treatment of complex perianal fistula: a phase II clinical trial. Dis Colon Rectum 2009; 52:79-86.
39. Guadalajara H, Herreros D, De-La-Quintana P, et al. Long-term follow-up of patients undergoing adipose-derived adult stem cell administration to treat complex perianal fistulas. Int J Colorectal Dis 2012; 27:595-600.
40. Ciccocioppo R, Bernardo ME, Sgarella A, et al. Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn's disease. Gut 2011; 60:788-798.
41. de la Portilla F, Alba F, Garcia-Olmo D, et al. Expanded allogeneic adipose-derived stem cells (eASCs) for the treatment of complex perianal fistula in Crohn's disease: results from a multicenter phase I/IIa clinical trial. Int J Colorectal Dis 2013; 28:313-323.
42. Herreros MD, Garcia-Arranz M, Guadalajara H, et al. Autologous expanded adipose-derived stem cells for the treatment of complex cryptoglandular perianal fistulas: a phase III randomized clinical trial (FATT 1 fistula Advanced Therapy Trial 1) and long-term evaluation. Dis Colon Rectum 2012; 55:762-772.
43. Duijvestein M, Vos AC, Roelofs H, et al. Autologous bone marrow-derived mesenchymal stromal cell treatment for refractory luminal Crohn's disease: results of a phase I study. Gut 2010; 59:1662-1669.
44. Liang J, Zhang H, Wang D, et al. Allogeneic mesenchymal stem cell transplantation in seven patients with refractory inflammatory bowel disease. Gut 2012; 61:468-469.
45. Forbes G, Sturm M, Leong R, et al. P590 Allogeneic mesenchymal strom al cells for biologicre fractory luminal Crohn's disease. J Crohn's Colitis 2013; 7:S247.
46. Lalu MM, McIntyre L, Pugliese C, et al. Safety of cell therapy with mesench-ymalstromal cells (SafeCell): asystematic reviewand meta-analysisof clinical trials. PLoS One 2012; 7:e47559.
47. Francois M, Romieu-Mourez R, Li M, Galipeau J. Human MSC suppression correlates with cytokine induction of indoleamine 2, 3-dioxygenase and by-stander M2 macrophage differentiation. Mol Ther 2012; 20:187-195.
48. Wu SM, Hochedlinger K. Harnessing the potential of induced pluripotent stem cells for regenerative medicine. Nat Cell Biol 2011; 13:497-505.
49. Yui S, Nakamura T, Sato T, et al. Functional engraftment of colon epithelium expanded in vitrofrom a single adult Lgr5(+) stem cell. Nat Med 2012;18:618-623.
50. Hippen KL, Merkel SC, Schirm DK, et al. Massive ex vivo expansion of human natural regulatory T cells (T(regs)) with minimal loss of in vivo functional activity. Sci Transl Med 2011; 3:83ra41.